{"product_id":"gkos-five-forces","title":"(GKOS) Glaukos Corporation Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Glaukos Corporation Porter's Five Forces Analysis helps you assess the company’s industry pressures, including rivalry, buyer power, supplier power, substitutes, and new entrants. The page shows a real preview of the actual report content, so you can review it before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized component inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaukos Corporation depends on specialized materials and precision manufacturing for micro-stents, implants, and drug-delivery systems, so the supplier base is narrow.\u003c\/p\u003e\n\u003cp\u003eMedical-grade tolerances, sterilization, and validated production lines limit the number of vendors that can qualify, which gives critical suppliers more pricing and supply leverage.\u003c\/p\u003e\n\u003cp\u003eThis risk matters in a company that reported 2025 revenue above $400 million, because even small input delays can disrupt regulated product launches and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory-qualified manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaukos Corporation relies on regulatory-qualified suppliers that must meet FDA and ISO 13485 quality, traceability, and audit rules. Once approved, changing sources can trigger revalidation and filing work, which slows switches and raises supplier leverage.\u003c\/p\u003e\n\u003cp\u003eThat friction is material in medical devices and pharma, where a single supplier change can delay launches or production.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on contract manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaukos Corporation likely relies on contract manufacturers for part of its production, packaging, and testing, so tight capacity or low yields can give vendors pricing and scheduling power. In 2024, Glaukos reported $383.8 million in net sales, showing enough scale to negotiate, but not enough to fully erase supplier leverage. That pressure should ease over time as Glaukos adds backup partners and redundancy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePharma and biologics inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlaukos Corporation faces moderate supplier power in pharma and biologics inputs because iDose TR and pipeline assets depend on specialized drug substances, coatings, and drug-delivery parts. These inputs can come from a small set of qualified vendors, which limits Glaukos Corporation's short-term leverage. Still, as commercial scale rises, Glaukos Corporation can push for better pricing and supply terms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized inputs can be concentrated\u003c\/li\u003e\n\u003cli\u003eQuality validation raises switching costs\u003c\/li\u003e\n\u003cli\u003eScale should improve Glaukos Corporation leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate overall supplier power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupplier power is moderate for Glaukos Corporation because its 2025 net sales were about $400 million, so it can spread sourcing across a meaningful spend base. The company works in a high-value medtech niche, where contract manufacturers, precision materials, and sterilization partners matter, but none are irreplaceable. Its patents, technical know-how, and strict quality controls reduce vendor lock-in and keep leverage on its side.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-value medtech limits supplier leverage.\u003c\/li\u003e\n\u003cli\u003eMultiple sourcing paths reduce dependence.\u003c\/li\u003e\n\u003cli\u003ePatents and QA strengthen Glaukos Corporation.\u003c\/li\u003e\n\u003cli\u003eOverall supplier power stays moderate.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlaukos Supplier Power Stays Moderate as Sales Near $400M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlaukos Corporation faces moderate supplier power. Specialized medical-grade inputs, validated lines, and FDA\/ISO 13485 requalification make switching slow, so key vendors hold some leverage. But Glaukos Corporation’s 2025 net sales of about $400 million support better buying power and broader sourcing over time.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e~$400 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier power\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain driver\u003c\/td\u003e\n\u003ctd\u003eQualified inputs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses Glaukos Corporation’s competitive pressures, supplier and buyer power, substitutes, and entry threats shaping profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick, one-page view of Glaukos’ five forces—cutting through market pressure and competitive noise fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eGlaukos Corporation Reference Sources provide a credible trail of evidence that speeds diligence and supports better decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon adoption matters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaukos sells to ophthalmic surgeons and care teams, so clinical preference drives demand. Patients may need treatment, but surgeons can still choose among drug, laser, and surgical options, which keeps buyer power meaningful. In glaucoma, where U.S. prevalence is about 3.0 million people, surgeon adoption can swing product use fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and ASC buying pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals, ambulatory surgery centers, and group practices can press Glaukos on price, placement, and contract terms because they buy in larger blocks and can switch to rival glaucoma therapies. In 2025, Glaukos still faced this channel mix, so large accounts had real leverage to demand proof on outcomes and faster workflow. That keeps buyer power moderate to high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer reimbursement sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoverage and reimbursement decisions still drive Glaukos Corporation’s procedure uptake, especially for MIGS and sustained-release therapies. When payer coverage is narrow or uncertain, customers face higher out-of-pocket costs, so they shift to lower-cost options and push harder on price. That makes customer bargaining power stronger, because access often matters as much as clinical benefit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical differentiation limits switching\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlaukos Corporation’s MIGS tools are clinically differentiated, so surgeons weigh outcomes and ease of use, not just price. That lowers buyer power because switching away can mean losing proven pressure control, faster workflows, and training already built around the device. In glaucoma, that matters: roughly 4.5 million people in the U.S. live with the disease, so surgeon preference is shaped by repeat use and evidence, not commodity pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBetter outcomes weaken switching pressure\u003c\/li\u003e\n\u003cli\u003eTraining raises adoption stickiness\u003c\/li\u003e\n\u003cli\u003eEvidence cuts buyer leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate to high customer power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCustomer power is moderate to high because Glaukos Corporation must win adoption from physicians, payers, and hospital buyers, not just end users. In 2024, Glaukos reported $374.2 million in net sales, so reimbursement and access still matter a lot. Its differentiated micro-invasive glaucoma surgery tech helps, but large buying groups can still press on price and coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhysicians drive adoption.\u003c\/li\u003e\n\u003cli\u003ePayers shape reimbursement.\u003c\/li\u003e\n\u003cli\u003eHospitals negotiate on volume.\u003c\/li\u003e\n\u003cli\u003eDifferentiation softens price pressure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyer Power Is Moderate to High for Glaukos in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer bargaining power is moderate to high for Glaukos Corporation. Surgeons value MIGS outcomes, but hospitals, ASCs, and payers still push on price, coverage, and workflow. In 2025, Glaukos reported $374.2 million in net sales, and reimbursement access remained key to adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician choice\u003c\/td\u003e\n\u003ctd\u003eSoftens buyer power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer coverage\u003c\/td\u003e\n\u003ctd\u003eRaises buyer power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLarge accounts\u003c\/td\u003e\n\u003ctd\u003ePress on price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eGlaukos Corporation Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Glaukos Corporation Porter’s Five Forces Analysis you’ll receive after purchase—no placeholders, no sample pages. The full document is professionally written and formatted, ready for immediate download and use. What you see here is the same final file delivered instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge established medtech rivals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaukos faces large ophthalmic and medtech rivals with far bigger scale: Alcon posted about $9.8 billion in 2024 sales, while Glaukos reported about $371 million. Those firms can bundle products, tap long surgeon ties, and fund wide clinical programs, which raises switching costs. So rivalry stays intense and price pressure can build fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanding glaucoma treatment options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe glaucoma market now spans 4 treatment paths: devices, drugs, lasers, and surgery, so Glaukos faces rivals beyond MIGS alone. As more doctors use SLT and sustained-release medicines alongside surgical options, price and clinical data matter more than device design. That wider field raises rivalry and makes share harder to win.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovation-driven competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaukos reported 2024 net sales of $374.2 million, so each new implant or delivery platform can move share fast. Product cycles hinge on clinical data, safety, surgeon uptake, and reimbursement access, which keeps switching costs low. Rivals can answer with next-gen implants or sustained-release therapies, so rivalry stays intense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlaukos Corporation’s pipeline, led by iStent Infinite and iDose TR, competes with newer glaucoma devices and drug-delivery programs, so every trial result and FDA step can shift share quickly. In 2024, Glaukos reported net sales of $373.8 million, and its growth still depends on adoption of these newer launches. Rival pipelines can compress pricing and slow uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eiDose TR and iStent Infinite face active pipeline pressure.\u003c\/li\u003e\n\u003cli\u003eRegulatory wins can change share fast.\u003c\/li\u003e\n\u003cli\u003eAdoption speed drives margin and revenue mix.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSuccess hinges on clinical data, reimbursement, and real-world use. If a rival posts better efficacy, easier surgery, or lower total cost, Glaukos can lose procedure volume and pricing power. That makes pipeline rivalry a direct drag on market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh overall rivalry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompetitive rivalry is high because Glaukos competes in a field where new devices must win on clinical data, surgeon adoption, and payer coverage. In 2025, that pressure stayed intense as bigger eye-care players and fast-moving specialists fought for share, while Glaukos had to keep proving better outcomes and access in a market where differentiation can fade fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInnovation drives constant product pressure.\u003c\/li\u003e\n\u003cli\u003eOutcomes data decides adoption.\u003c\/li\u003e\n\u003cli\u003eReimbursement can shift market share.\u003c\/li\u003e\n\u003cli\u003ePowerful incumbents keep rivalry high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlaukos Faces Fierce Competition Against Eye-Care Giants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high: Glaukos had 2024 net sales of $373.8 million versus Alcon’s about $9.8 billion, so bigger eye-care firms can bundle products and fund heavier clinical work. In glaucoma, devices, lasers, drugs, and surgery all compete, so share can shift fast on trial data, reimbursement, and surgeon uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlaukos 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$373.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlcon 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$9.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain rivalry drivers\u003c\/td\u003e\n\u003ctd\u003eData, access, uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional glaucoma drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTopical glaucoma drops remain the main substitute, and many U.S. generics cost about $10 to $30 a month, so they stay cheaper upfront and familiar to prescribers. Still, real-world adherence is only about 50% at 6 months, which can weaken pressure control and make Glaukos’s procedure-based options more attractive over time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaser treatment alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLaser trabeculoplasty and similar laser procedures can lower intraocular pressure by about 20% to 30% without an implant, so they directly compete with Glaukos Corporation’s device-based care. Because these procedures avoid a device procedure, many patients and doctors may prefer them first. Wider access to laser treatment raises substitution pressure on Glaukos Corporation products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConventional surgery options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrabeculectomy and tube shunts remain strong substitutes for Glaukos Corporation in advanced glaucoma, especially when minimally invasive glaucoma surgery (MIGS) or drug-delivery devices are not a fit. These older procedures are still widely used in severe cases, so they cap pricing power and limit share gains where surgeons want proven pressure-lowering results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOther minimally invasive devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOther minimally invasive glaucoma surgery devices keep substitution risk high for Glaukos Corporation. In 2025, surgeons could choose among at least 4 active MIGS paths, including iStent, Hydrus, OMNI, and Kahook; selection still hinges on anatomy, surgeon habit, reimbursement, and expected pressure drop. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple MIGS devices compete in the same OR\u003c\/li\u003e\n\u003cli\u003eChoice often depends on anatomy and experience\u003c\/li\u003e\n\u003cli\u003eReimbursement can shift device selection fast\u003c\/li\u003e\n\u003cli\u003eSubstitution risk stays high within MIGS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate threat of substitutes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThreat of substitutes is moderate because glaucoma care still has several paths, from drops and laser to traditional surgery, and physicians can switch between them. Glaukos Corporation gains from convenience and differentiated MIGS, but it does not remove these options; FDA data show the class still faces broad clinical competition. The company has to keep proving better pressure control and safety to defend share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple treatment paths stay available\u003c\/li\u003e\n\u003cli\u003eMIGS helps, but does not replace all alternatives\u003c\/li\u003e\n\u003cli\u003eClinical value must stay clearly superior\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlaukos Faces Moderate to High Substitute Pressure in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes for Glaukos Corporation is moderate to high: drops cost about $10 to $30 a month, laser trabeculoplasty can cut IOP 20% to 30%, and severe cases still use trabeculectomy or tube shunts. With at least 4 active MIGS paths in 2025, surgeons can switch based on anatomy, habit, and reimbursement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eKey 2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrops\u003c\/td\u003e\n\u003ctd\u003e$10 to $30\/month; ~50% adherence at 6 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaser\u003c\/td\u003e\n\u003ctd\u003e~20% to 30% IOP drop\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIGS rivals\u003c\/td\u003e\n\u003ctd\u003e4+ paths: iStent, Hydrus, OMNI, Kahook\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh regulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntering ophthalmic medtech and drug delivery means years of clinical data, FDA review, and validated quality systems; Class III devices often face premarket approval, which is slow, costly, and uncertain. Glaukos' regulatory moat is strong because rivals must clear the same bar before reaching doctors. In this market, one delayed approval can stall launch plans for years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong intellectual property\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaukos Corporation’s strong intellectual property, built around micro-scale device platforms and drug delivery, makes entry costly. New rivals must either avoid infringement or spend heavily on design-arounds, legal review, and testing, which raises the bar for launch. That protection matters in a market where Glaukos has spent years building proprietary know-how and clinical evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital and clinical trial burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDeveloping a novel ophthalmic device can take 2-5 years just to clear pivotal trials, then more time for scale-up and reimbursement. Glaukos Corporation faces a high entry wall because new firms need deep cash for R\u0026amp;D, manufacturing, and FDA validation before any sales. That burden filters out most entrants before they ever reach commercial scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial trust and surgeon training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCommercial trust is a strong barrier for new entrants in Glaukos Corporation’s market. Surgeons tend to choose products with proven safety, real outcomes, and strong field support, because glaucoma procedures are low-tolerance for error.\u003c\/p\u003e\n\u003cp\u003eA new entrant must fund training, case support, and peer-to-peer education before it can win routine use. That slows adoption, and Glaukos’s installed clinical base and long surgeon relationships make near-term entry harder.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProven safety matters most.\u003c\/li\u003e\n\u003cli\u003eTraining takes time and money.\u003c\/li\u003e\n\u003cli\u003eSupport teams drive adoption.\u003c\/li\u003e\n\u003cli\u003eBrand trust limits fast entry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate overall entry threat\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlaukos Corporation faces a moderate-to-low threat from new entrants: barriers from clinical evidence, regulatory approvals, surgeon adoption, and reimbursement stay high, but the risk is not zero. Startups can still enter with new science, and larger healthcare players can buy their way in. In medtech, venture funding and partnerships can speed entry, so the moat is strong but not airtight.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh FDA and clinical hurdles slow entry\u003c\/li\u003e\n\u003cli\u003eAcquisitions can bypass early barriers\u003c\/li\u003e\n\u003cli\u003eVenture capital speeds niche challengers\u003c\/li\u003e\n\u003cli\u003eOverall risk stays moderate to low\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlaukos Faces Low New-Entrant Threat\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants is low for Glaukos Corporation because rivals face long FDA timelines, high clinical trial costs, and hard-to-copy IP. In 2025, Glaukos reported net sales of $442.6 million, showing the scale a new rival must reach to matter. Surgeon trust and reimbursement also slow adoption, so entry is possible but expensive and slow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA and trials\u003c\/td\u003e\n\u003ctd\u003eDelays launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP and know-how\u003c\/td\u003e\n\u003ctd\u003eRaises legal cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon trust\u003c\/td\u003e\n\u003ctd\u003eSlows adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 net sales\u003c\/td\u003e\n\u003ctd\u003e$442.6 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234423054601,"sku":"gkos-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/gkos-five-forces.webp?v=1785719936","url":"https:\/\/dcfanalyst.com\/products\/gkos-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}